Send to

Choose Destination
PLoS One. 2016 Oct 24;11(10):e0165382. doi: 10.1371/journal.pone.0165382. eCollection 2016.

Evaluation of CD146 as Target for Radioimmunotherapy against Osteosarcoma.

Author information

Oncoinvent AS, Oslo, Norway.
Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Department of Oncology, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
Sciencons AS, Oslo, Norway.



Osteosarcoma is a rare form of cancer but with a substantial need for new active drugs. There is a particular need for targeted therapies to combat metastatic disease. One possible approach is to use an antibody drug conjugate or an antibody radionuclide conjugate to target the osteosarcoma metastases and circulating tumor cells. Herein we have evaluated a radiolabeled monoclonal antibody targeting CD146 both in vitro and in vivo.


A murine monoclonal anti-CD146 IgG1 isotype antibody, named OI-3, was developed along with recombinant chimeric versions with human IgG1 or human IgG3 Fc sequences. Using flow cytometry, selective binding of OI-3 to human osteosarcoma cell lines OHS, KPDX and Saos-2 was confirmed. The results confirm a higher expression level of CD146 on human osteosarcoma cells than HER2 and EGFR; antigens targeted by commercially available therapeutic antibodies. The biodistribution of 125I-labeled OI-3 antibody variants was compared with 125I-labeled chimeric anti-EGFR antibody cetuximab in nude mice with subcutaneous OHS osteosarcoma xenografts. OI-3 was able to target CD146 expressing tumors in vivo and showed improved tumor to tissue targeting ratios compared with cetuximab. Subsequently, the three OI-3 variants were conjugated with p-SCN-Bn-DOTA and labeled with a more therapeutically relevant radionuclide, 177Lu, and their biodistributions were studied in the nude mouse model. The 177Lu-labeled OI-3 variants were stable and had therapeutically relevant biodistribution profiles. Dosimetry estimates showed higher absorbed radiation dose to tumor than all other tissues after administration of the chimeric IgG1 OI-3 variant.


Our results indicate that CD146 can be targeted in vivo by the radiolabeled OI-3 antibodies.

[Indexed for MEDLINE]
Free PMC Article

Conflict of interest statement

Competing Interests: The OI-3 monoclonal antibody is a patented product from Oncoinvent AS. Sara Westrøm and Tina B. Bønsdorff are employed by Oncoinvent AS, and Nasir Abbas and Thora J. Jonasdottir were employed by Oncoinvent AS at the time when their main contribution to the research article occurred. Oncoinvent AS provided support in the form of salaries for authors SW, TBB, NA and TJJ, but did not have any additional role in the study design, data collection and analysis, or preparation of the manuscript. Øyvind S. Bruland, Thora J. Jonasdottir and Roy H. Larsen are members of the Board of Oncoinvent AS, and the three of them together with Tina B. Bønsdorff are shareholders of Oncoinvent AS. Roy H. Larsen is also affiliated to Sciencons AS which is a shareholder of Oncoinvent AS. Sciencons AS did not provide support in the form of salaries for author Roy H. Larsen, and did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. A patent application related to the OI-3 antibody versions described in the submitted manuscript has previously been filed (Patent name: Monoclonal antibody and derivatives. Patent number: PCT/EP2014/070395). The authors confirm that these competing interests do not alter their adherence to PLOS ONE policies on sharing data and materials.

Supplemental Content

Full text links

Icon for Public Library of Science Icon for PubMed Central Icon for Norwegian BIBSYS system
Loading ...
Support Center